Whole-Body Photobiomodulation Use in Professional Soccer Players During a State Championship
Universidade Federal de Sao Carlos
24 participants
Sep 4, 2025
INTERVENTIONAL
Conditions
Summary
This study aims to investigate the effects of whole-body photobiomodulation on professional soccer players during a state championship. The primary question is whether photobiomodulation improves recovery, reduces muscle fatigue, and enhances performance compared to standard training without photobiomodulation.
Eligibility
Inclusion Criteria5
- Male professional soccer players currently competing in the championship
- Age 18-35 years
- Training frequency ≥5 times per week
- Able to attend all PBM/sham sessions and all assessments during the 8-week intervention
- Signed informed consent
Exclusion Criteria5
- Lower-limb musculoskeletal injury in the last 6 months or currently receiving treatment
- Current use of phototherapy or any other recovery-enhancing modality
- Chronic medical conditions that may affect performance or recovery
- Known sensitivity or contraindication to light-based therapies
- Inability to comply with the intervention or training schedule
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This intervention consists of whole-body photobiomodulation delivered using a full-body PBM device. Sessions are performed twice weekly on non-consecutive days for 8 weeks, coinciding with the athletes' standard training. The device emits therapeutic light at specified wavelengths and power, targeting the entire body. The protocol is standardized according to prior research, ensuring consistent exposure for all participants in the active arm. The intervention aims to improve muscle performance and recovery while reducing delayed onset muscle soreness (DOMS).
Intervention Description (Sham PBM): Participants receive a sham photobiomodulation intervention using the same device and schedule, but without emission of therapeutic light. The procedure mimics the active intervention to maintain blinding while allowing comparison of outcomes, including muscle performance, DOMS, and blood markers.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07224646